Cargando…
A Drug Discovery Approach for an Effective Pain Therapy through Selective Inhibition of Nav1.7
Chronic pain is a widespread disorder affecting millions of people and is insufficiently addressed by current classes of analgesics due to significant long-term or high dosage side effects. A promising approach that was recently proposed involves the systemic inhibition of the voltage-gated sodium c...
Autores principales: | Trombetti, Gabriele A., Mezzelani, Alessandra, Orro, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223482/ https://www.ncbi.nlm.nih.gov/pubmed/35743236 http://dx.doi.org/10.3390/ijms23126793 |
Ejemplares similares
-
Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors
por: Chernov-Rogan, Tania, et al.
Publicado: (2018) -
Pain without Nociceptors? Nav1.7-Independent Pain Mechanisms
por: Minett, Michael S., et al.
Publicado: (2014) -
Inhibition of the Nav1.7 Channel in the Trigeminal Ganglion Relieves Pulpitis Inflammatory Pain
por: Kwon, Minjee, et al.
Publicado: (2021) -
Discovery of aryl sulfonamide-selective Nav1.7 inhibitors with a highly hydrophobic ethanoanthracene core
por: Wang, Jin-tao, et al.
Publicado: (2019) -
Lidocaine reduces pain behaviors by inhibiting the expression of Nav1.7 and Nav1.8 and diminishing sympathetic sprouting in SNI rats
por: Li, Xiaoxiao, et al.
Publicado: (2022)